This is an international site for Exjade® (Deferasirox) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.

I am a healthcare professional I am a patient inside of the US I am a patient outside the U.S.

Home > Transfusion-Dependent β-Thalassemia > T2* and Cardiac Iron
Print

In this section:

EU SmPC
T2 and Cardiac Iron

T2* as a Measure of Cardiac Iron Burden

MRI has been investigated and shown to be a reliable tool for quantifying iron stores in cardiac tissue in addition to the liver and the anterior pituitary.

Cardiac T2* as measured by MRI has been shown to be more reliable in determining iron loading in the heart when compared with liver iron concentrations and/or serum ferritin levels.1,2,3

Cardiac iron thresholds are indicated by T2* values2,4
  • <10 ms correlates with severe cardiac siderosis
  • 10-20 ms indicates mild-moderate cardiac iron toxicity
  • >20 ms is indicative of normal levels in the heart

EXJADE PROVIDES
TOTAL BODY
CHELATION

EXJADE has been
shown to reduce LIC and
serum ferritin, and
improve myocardial T2*.

Learn more

LEARN MORE ABOUT
OPTIMIZING PATIENT
TREATMENT WITH
TAILORED EXJADE
DOSING

Use the Dosing Simulator

References

  1. Kirk P, Roughton M, Porter JB, et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation. 2009; 120:1961-1968.
  2. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;(22):2171-2719.
  3. Patton N, Brown G, Leung M, et al. Observational study of iron overload as assessed by magnetic resonance imaging in an adult population of transfusion dependent patients with β thalassaemia: significant association between low cardiac T2* <10 ms and cardiac events. Internal Med J. 2010;40(6):419-426.
  4. Pennell DJ, Porter JB, Cappellini MD, et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia. Blood. 2010;115(12):2364-2371.
TRANSFUSION-DEPENDENT
β-THALASSEMIA		 MYELODYSPLASTIC SYNDROMES SICKLE CELL DISEASE APLASTIC AND OTHER ANEMIAS TOOLS AND RESOURCES ALL ABOUT EXJADE

EXJADE is indicated for the treatment of chronic iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) in patients with β-thalassemia major aged 6 years and older.

EXJADE is also indicated for the treatment of chronic iron overload due to blood transfusion in patients aged 2 years and older with β-thalassemia major or other anemias when deferoxamine is contraindicated or inadequate.
Disclaimer: This is an international website for Exjade, and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
© Novartis AG | Use of this website is subject to our Terms of Use | About Novartis Oncology | Privacy | Site Map | Contact Us | EU SmPC | Safety Information | PubMed